drugset / Trial / NCT07255404
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Phase 2
Recruiting
105 enrolled
BioNTech SE
BioNTech (Shanghai) Pharmaceuticals Co., Ltd. · collabBristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment naïve), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function. Participants will receive pumitamig (BNT327) in combination with chemotherapy.
Timeline
- Start
- 2025-12-04
- Primary completion
- 2027-12
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Pumitamig | Protein / enzyme biologic | — | Intravenous |